Organon (OGN) Fiscal Q2 Revenue Beats 1%

Core Insights - Organon reported fiscal Q2 2025 results with GAAP revenue of $1.59 billion, exceeding analyst expectations, but both revenue and earnings declined compared to the previous year [1][2] - The company is focusing on new product growth while facing challenges with its legacy product portfolio [1][4] Financial Performance - GAAP revenue for Q2 2025 was $1.59 billion, slightly down from $1.61 billion in Q2 2024, but above estimates by $42 million [2][5] - Non-GAAP adjusted EPS was $1.00, beating the consensus estimate of $0.95, but down 11% from $1.12 in Q2 2024 [2][5] - Net income (GAAP) fell to $145 million from $195 million year-over-year, a decline of 25.6% [2][10] - Adjusted EBITDA (non-GAAP) increased by 1.8% to $522 million, with a margin improvement to 32.7% [2][9] Business Segments - Women's Health segment generated $462 million in sales, up 3%, driven by a 15% increase in fertility treatments [5][6] - Biosimilars revenue rose 5% to $173 million, primarily due to Hadlima, which contributed $50 million [6][8] - Established brands revenue was $936 million, down 3% year-over-year, with notable declines in Atozet and Singulair due to competition [7][8] Strategic Focus - Organon is prioritizing growth in women's health, diversifying its biosimilars portfolio, and managing its mature product lines amid generic competition [4][12] - The company aims to launch new products and expand internationally while managing costs and reducing debt [4][11] Outlook - Full-year revenue guidance for 2025 was raised to $6.275 billion–$6.375 billion, reflecting improved expectations due to foreign exchange factors [12] - Adjusted EBITDA margin guidance remains at 31.0%–32.0%, with a focus on achieving a net leverage ratio below 4.0x by year-end 2025 [12][13]